Organization (Academic)
Korea University
ClinicalTrials.gov lists Korea University as lead sponsor of 269 trials, counting the companies grouped under it. Korea University itself has 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Korea University, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Korea University and 3 companies grouped under it: 269 lead-sponsored trials (64 its own, 205 in the grouped companies) and 5 legal-entity registrations (2 its own, 3 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Korea University Anam Hospital | 110 | 1 |
| Korea University Guro Hospital | 87 | 1 |
| Korea University Ansan Hospital | 8 | 1 |
Disease areas (224)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 35 |
| Coronary Disease | 31 |
| Atherosclerosis | 27 |
| Coronary Artery Disease | 27 |
| Atrial Fibrillation | 23 |
Showing 5 of 224 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 7 |
| 2024 | 3 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 5 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ciprofloxacin | 2 |
| ADEFOVIR, LAMIVUDINE | 1 |
| combination of lamivudine+adefovir vs entecavir | 1 |
| Ingenol mebutate gel 0.05 % | 1 |
| telbivudine plus adefovir | 1 |
Showing 5 of 23 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | 0 of 1 on time (n=1) |
Journals published in (387)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 40 |
| Circulation | 33 |
| European heart journal | 33 |
| Hepatology (Baltimore, Md.) | 26 |
| Journal of the American College of Cardiology | 24 |
Showing 5 of 387 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 13 | 0 | 2018-08-14 |
Organization relationships (99)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Samsung (South Korea) | Co sponsors trial with | 25 |
| The Catholic University of Korea | Co sponsors trial with | 19 |
| Yonsei University | Co sponsors trial with | 19 |
| Seoul National University | Co sponsors trial with | 17 |
| Inje University | Co sponsors trial with | 17 |
Showing 5 of 99 relationships.
Latest dated events (429)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 429 events.
Biomarker capability evidence (70)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial sponsor | Named in trial inclusion criteria |
| AFP | Trial sponsor | Named in trial inclusion criteria |
| AFP | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 70 evidence rows.
Biomarkers this organization publishes on (638)
Shown in this order: most publications first.
Showing 5 of 638 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.